Clinical characteristics and prognostic analysis of Chinese patients with diffuse large B-cell lymphoma

Blood Cells, Molecules, and Diseases

Volumn 44, Issue 1, 2010, Pages 55-61

  Ke, Xiaoyan ^a   Wang, Jing ^a   Gao, Zifen ^b   Zhao, Lingzhi ^a   Li, Min ^b   Jing, Hongmei ^a   Wang, Jijun ^a   Zhao, Wei ^a   Gilbert, Heather ^c   Yang, Xiao Feng ^d  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c ARUP LABORATORIES   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell origin of tumor; Diffuse large B cell lymphoma; International prognostic index; Lactate dehydrogenase; Prognostic analysis

Indexed keywords

BETA 2 MICROGLOBULIN; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; PREDNISOLONE; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CANCER STAGING; CANCER SURGERY; CHINA; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; GERMINAL CENTER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

AGED; AGING; ANTIGENS, NEOPLASM; ASIAN CONTINENTAL ANCESTRY GROUP; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; DNA-BINDING PROTEINS; FEMALE; GERMINAL CENTER; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LACTATE DEHYDROGENASES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; NEPRILYSIN; ORGAN SPECIFICITY; PROGNOSIS;

EID: 73049101143     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2009.09.002     Document Type: Article

References (29)

1. Shipp M.A. Molecular signatures define new rational treatment targets in large B-cell lymphomas. Hematol. Am. Soc. Hematol. Educ. Program 2007 (2007) 265-269
2. Sehn L.H., Berry B., Chhanabhai M., Fitzgerald C., Gill K., Hoskins P., Klasa R., Savage K.J., Shenkier T., Sutherland J., et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109 (2007) 1857-1861
3. Ke X., Zhao L., Gao Z., Wang J., Dong F., Zhou X., Shi L., Huang X., Jing H., Wang J., et al. Higher rates of t(11;18) in Chinese patients with transformed type of MALT lymphoma suggest novel pathways for progression of the disease. Leuk. Lymphoma 48 (2007) 2157-2166
4. Wang X.Q. [Cytogenetic study on 155 cases of non-Hodgkin' s lymphoma]. Zhonghua Xue Ye Xue Za Zhi 27 (2006) 656-660
5. In: Jaffe E., Harris N.K., Stein H., and Vardiman J.W. (Eds). World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues (2001), IARC Press, Lyon
6. Conconi A., Zucca E., Roggero E., Bertoni F., Bernasconi A., Mingrone W., Pedrinis E., and Cavalli F. Prognostic models for diffuse large B-cell lymphoma. Hematol. Oncol. 18 (2000) 61-73
7. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346 (2002) 235-242
8. Habermann T.M., Weller E.A., Morrison V.A., Gascoyne R.D., Cassileth P.A., Cohn J.B., Dakhil S.R., Woda B., Fisher R.I., Peterson B.A., et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J. Clin. Oncol. 24 (2006) 3121-3127
9. Cleary M.L., Chao J., Warnke R., and Sklar J. Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma. Proc. Natl. Acad. Sci. U. S. A. 81 (1984) 593-597
10. Trainor K.J., Brisco M.J., Wan J.H., Neoh S., Grist S., and Morley A.A. Gene rearrangement in B- and T-lymphoproliferative disease detected by the polymerase chain reaction. Blood 78 (1991) 192-196
11. Uchiyama M., Maesawa C., Yashima A., Itabashi T., Ishida Y., and Masuda T. Consensus primers for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell lymphomas. J. Clin. Pathol. 56 (2003) 778-779
12. Jerkeman M., Anderson H., Dictor M., Kvaloy S., Akerman M., and Cavallin-Stahl E. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study. Ann. Hematol. 83 (2004) 414-419
13. Xu Y., McKenna R.W., and Kroft S.H. Comparison of multiparameter flow cytometry with cluster analysis and immunohistochemistry for the detection of CD10 in diffuse large B-Cell lymphomas. Mod. Path. 15 (2002) 413-419
14. Colomo L., Lopez-Guillermo A., Perales M., Rives S., Martinez A., Bosch F., Colomer D., Falini B., Montserrat E., and Campo E. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 101 (2003) 78-84
15. Ree H.J., Yang W.I., Kim C.W., Huh J., Lee S.S., Cho E.Y., Ko Y.H., and Charney D. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma. Human Pathol. 32 (2001) 954-962
16. Zhang A., Ohshima K., Sato K., Kanda M., Suzumiya J., Shimazaki K., Kawasaki C., and Kikuchi M. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas. Pathol. Int. 49 (1999) 1043-1052
17. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., Muller-Hermelink H.K., Campo E., Braziel R.M., Jaffe E.S., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 (2004) 275-282
18. Chang C.C., McClintock S., Cleveland R.P., Trzpuc T., Vesole D.H., Logan B., Kajdacsy-Balla A., and Perkins S.L. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am. J. Surg. Pathol. 28 (2004) 464-470
19. Barrans S.L., Carter I., Owen R.G., Davies F.E., Patmore R.D., Haynes A.P., Morgan G.J., and Jack A.S. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99 (2002) 1136-1143
20. Jerkeman M., Aman P., Cavallin-Stahl E., Torlakovic E., Akerman M., Mitelman F., and Fioretos T. Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study. Int. J. Oncol. 20 (2002) 161-165
21. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat. Rev., Cancer 5 (2005) 251-262
22. Choi H.B., Roh S.Y., Choi E.J., Yoon H.Y., Kim S.Y., Hong Y.S., Kim D.W., and Kim T.G. Association of HLA alleles with non-Hodgkin's lymphoma in Korean population. Int. J. Hematol. 87 (2008) 203-209
23. Kim S., Sunwoo J.B., Yang L., Choi T., Song Y.J., French A.R., Vlahiotis A., Piccirillo J.F., Cella M., Colonna M., et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 3053-3058
24. Shipp M.A., Ross K.N., Tamayo P., Weng A.P., Kutok J.L., Aguiar R.C., Gaasenbeek M., Angelo M., Reich M., Pinkus G.S., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 8 (2002) 68-74
25. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
26. Saez A.I., Saez A.J., Artiga M.J., Perez-Rosado A., Camacho F.I., Diez A., Garcia J.F., Fraga M., Bosch R., Rodriguez-Pinilla S.M., et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am. J. Pathol. 164 (2004) 613-622
27. Zhang W., Li L., Li X., Jiang W., Huo J., Wang Y., Lin M., and Rao S. Unravelling the hidden heterogeneities of diffuse large B-cell lymphoma based on coupled two-way clustering. BMC Genomics 8 (2007) 332
28. Li S., Phong M., Lahn M., Brail L., Sutton S., Lin B.K., Thornton D., and Liao B. Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas. Biol. Direct 2 (2007) 8
29. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., Gascoyne R.D., Muller-Hermelink H.K., Smeland E.B., Giltnane J.M., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346 (2002) 1937-1947